MARKET

MYGN

MYGN

Myriad Genetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

33.72
+1.10
+3.37%
After Hours: 33.72 0 0.00% 16:19 09/17 EDT
OPEN
32.86
PREV CLOSE
32.62
HIGH
33.74
LOW
32.46
VOLUME
1.06M
TURNOVER
--
52 WEEK HIGH
36.95
52 WEEK LOW
11.76
MARKET CAP
2.63B
P/E (TTM)
-21.5518
1D
5D
1M
3M
1Y
5Y
Predisposition Biomarkers Market- Expected Growth and its Factors, CAGR, Industry Size, Business Prospects and Forecast 2030
Research Nester published a report titled which delivers detailed overview of the global predisposition biomarkers market in terms of market segmentation by type, application, end-user, and by region.
AmericaNewsHour · 2d ago
LabCorp (LH) Bolsters RA Testing by Adding Myriad's Vectra
Zacks.com · 3d ago
Only 8% of people remain hopeful after depression medication fails them, according to GeneSight® Mental Health Monitor nationwide survey
SALT LAKE CITY, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Depression medication trial and error is far too common – and may result in additional mental health challenges. When people with depression take a medication that does not help them, they reported feeling...
GlobeNewswire · 09/08 20:05
Illumina (ILMN), Merck Ink Cancer Companion Diagnostics Deal
Illumina (ILMN) collaborated with Merck to develop and commercialize companion diagnostics to identify ovarian cancer patients with positive HRD status for treatment with LYNPARZA.
Zacks · 09/08 12:36
Illumina, Merck to Collaborate Over Diagnostic Tests For Cancer Mutations
MT Newswires · 09/07 11:26
Agilent (A) Boosts PD-L1 IHC 22C3 pharmDX Assay Use in Europe
Zacks.com · 08/24 15:44
Tryp Therapeutics Appoints Dennis Langer, M.D., J.D. as Senior Advisor
San Diego, California--(Newsfile Corp. - August 18, 2021) - (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the appointm...
Newsfile Corp · 08/18 11:05
Insider Trends: Insider at Myriad Genetics Continues Selling Trend with Tax Sale
MT Newswires · 08/16 19:10
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MYGN. Analyze the recent business situations of Myriad Genetics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MYGN stock price target is 30.25 with a high estimate of 42.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 333
Institutional Holdings: 87.45M
% Owned: 112.03%
Shares Outstanding: 78.06M
TypeInstitutionsShares
Increased
70
3.44M
New
26
2.52M
Decreased
61
3.60M
Sold Out
22
786.37K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.10%
Healthcare Equipment & Supplies
+0.65%
Key Executives
Chairman/Independent Director
S. Louise Phanstiel
President/Chief Executive Officer/Director
Paul Diaz
Chief Financial Officer/Executive Vice President/Treasurer
R. Bryan Riggsbee
Corporate Executive
Melissa Gonzales
Corporate Executive
Nicole Lambert
Corporate Executive
Mark Verratti
Corporate Executive
Faith Zaslavsky
Executive Vice President/General Counsel/Secretary
Benjamin Jackson
Executive Vice President/Director of Human Resources
Jayne Hart
Executive Vice President
Paul Parkinson
Senior Vice President/Chief Marketing Officer
Jeff Borcherding
Senior Vice President
Maggie Ancona
Senior Vice President
Edward Gala
Senior Vice President
David Hammer
Senior Vice President
Chris Williamson
Chief Technology Officer
Kevin Haas
Chief Scientific Officer
Jerry Lanchbury
Vice President
Justin Hunter
Vice President
Karen Renner
Vice President - Business Development
Jackie Zou
Other
Eric Santa
Other
Thomas Slavin
Other
Gwendolyn Turner
Independent Director
Heiner Dreismann
Independent Director
Rashmi Kumar
Independent Director
Dennis Langer
Independent Director
Lee Newcomer
Independent Director
Colleen Reitan
Independent Director
Daniel Skovronsky
Independent Director
Daniel Spiegelman
No Data
  • All
  • Financials
  • Insiders
More
About MYGN
Myriad Genetics, Inc. (Myriad) is a genetic testing and precision medicine company. Myriad is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. It operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can progress patient care. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. The Company's products include myRisk, BRACAnalysis, BRACAnalysis CDx myChoice CDx, Prolaris, EndoPredict, Foresight and Prequel.

Webull offers kinds of Myriad Genetics, Inc. stock information, including NASDAQ:MYGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MYGN stock methods without spending real money on the virtual paper trading platform.